A Study to Investigate the Influence of Hepatic Impairment on MK-8189 Treatment (MK-8189-012)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 17, 2021

Primary Completion Date

January 16, 2022

Study Completion Date

January 25, 2022

Conditions

Hepatic Impairment

Interventions

DRUG

MK-8189

Administered at a dose of 4 mg via oral tablet

Trial Locations (2)

Clinical Pharmacology of Miami ( Site 0001), Miami

ProSciento Inc. ( Site 0002), Chula Vista

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT04676425 - A Study to Investigate the Influence of Hepatic Impairment on MK-8189 Treatment (MK-8189-012) | Biotech Hunter | Biotech Hunter